Date
4 February 2026

Time
 11:00-12:00 EST | 16:00-17:00 GMT | 17:00-18:00 CET

Key features

In this webinar we will discuss why dsRNA is undesirable as it can negatively impact the efficacy of mRNA products and patient safety by triggering various cascades in the innate immune system, typically associated with the response to virally infected cells.We will discuss strategies to analyse and characterize dsRNA and also put forward our suggestion of how safety limits should be assessed.

What you’ll learn:

• How dsRNA impurity is generated in in vitro reactions
• The regulatory landscape and expectations for control of impurities in mRNA-based products
• Current analytical methods for quantification and characterization of dsRNA
• Setting safety limits for dsRNA